Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis | MicrobiomeTrials← Back to trialsNCT05788705
Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis
CompletedNAINTERVENTIONAL
Trial Details
Start: 2025-04-05Est. Completion: 2026-06-01
Enrollment target: 60 participants Locations- Assiut university, Asyut, Egypt
Other microbiome trials you might be interested in
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030
Rheumatic DiseasesLupus Erythematosus, SystemicLupus Vasculitis, Central Nervous SystemArthritisSpondylarthritisAnkylosing SpondylarthritisRheumatoid ArthritisSjogren's Syndrome
Background:
Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause…
Bethesda, United States
Est. completion Jun 15, 2033
Rheumatoid Arthritis
Personalized medicine in which each patient would receive the ideal personalized treatment and regimen, holds great prom…
Montpellier, FranceCompleted Sep 16, 2026